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a  b  s  t  r  a  c  t
Chronic  exposure  to  inorganic  arsenic  (iAs)  is  carcinogenic  to the  human  urinary  bladder.  It  produces
urothelial  cytotoxicity  and  proliferation  in  rats  and mice.  DMAV, a major  methylated  urinary  metabolite
of  iAs,  is a rat  bladder  carcinogen,  but  without  effects  on  the mouse  urothelium.  DMAIII was  shown  to
be the  likely  urinary  metabolite  of  DMAV inducing  urothelial  changes  and  is  also  postulated  to be one
of  the  active  metabolites  of iAs.  To  evaluate  potential  DMAIII-induced  urothelial  effects,  it was  adminis-
tered  to As3mt  knockout  mice  which  cannot  methylate  arsenicals.  Female  C57BL/6  wild  type  and  As3mt
knockout  mice  (10/group)  were  administered  DMAIII, 77.3  ppm  in water  for four  weeks.  Urothelial  effects
were evaluated  by light  and  scanning  electron  microscopy  (EM)  and  immunohistochemical  detection  of
bromodeoxyuridine  (BrdU)  incorporation.  EM findings  were  rated 1–5, with  higher  rating  indicating
greater  extent  of  cytotoxicity  visualized.  DMAIII significantly  increased  the BrdU  labeling  index,  a ratio
of  BrdU  labeled  cells  to non-labeled  cells,  in  the  treated  knockout  group  compared  to control  and  wild
type treated  groups.  DMAIII induced  simple  hyperplasia  in more  knockout  mice  (4/10)  compared  to  wild
type mice  (2/10).  All  treated  knockout  mice  had  more  and  larger  intracytoplasmic  granules  compared
to the  treated  wild  type  mice.  Changes  in EM classification  were  not  significant.  In  conclusion,  DMAIII
induces  urothelial  toxicity  and regenerative  hyperplasia  in mice  and  most  likely  plays  a role  in inorganic
arsenic-induced  urothelial  changes.  However,  DMAV does  not  induce  hyperplasia  in mice,  suggesting
that  urinary  concentrations  of DMAIII do  not  reach  cytotoxic  levels  in  DMAV-treated  mice.
© 2013 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Inorganic arsenic (iAs) is a known human carcinogen pro-
ducing tumors in urinary bladder, liver, lung, and skin (National
Research Council, 1999, 2001). This metalloid occurs mainly in
the +5 (arsenate) or +3 (arsenite) oxidation states, and is the
20th most abundant chemical in the earth’s crust (IARC, 2004).
Because it is present in soils, it can be leached into ground water.
As-contaminated ground water is used as drinking water by popu-
lations worldwide and constitutes an important source of exposure
to this toxicant that is associated with increased incidence of both
cancer and non-cancer health effects (Chiou et al., 1995). Although
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dose–response relations for these adverse health effects are not
fully understood (Lamm et al., 2006), it is clear that arsenic expo-
sure contributes to tumor risk (National Research Council, 1999,
2001).
Elucidating the processes underlying the adverse health effects
of chronic arsenic exposure is complicated by the extensive
metabolism that follows ingestion or inhalation of iAs. Mono-, di-,
and trimethylated metabolites are found in tissues and excreta of
animals exposed to iAs. The formation of methylated arsenicals
is catalyzed in many mammalian species by arsenic (3+ oxidation
state) methyltransferase (As3mt) (Thomas et al., 2007). In the Chal-
lenger scheme, a series of reactions starting with arsenite produces
methylarsonic acid (MMAV) which is reduced to methylarsonous
acid (MMAIII) that is converted to dimethylarsinic acid (DMAV) and
reduced to form dimethylarsinous acid (DMAIII). In some species,
particularly rats and to lesser extent other rodents, DMAIII is further
methylated to form trimethylarsine oxide (TMAVO) (Adair et al.,
2007). TMAVO is only formed in humans when there is very high
exposure to inorganic arsenic (Aposhian, 1997; Cohen et al., 2006;
Thomas, 2007). These methylated metabolites of iAs exert specific
0300-483X/$ – see front matter ©  2013 Elsevier Ireland Ltd. All rights reserved.
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toxicities in animal models. For example, DMAV produces urinary
bladder tumors in rats but is not carcinogenic in mice (Arnold et al.,
2006; Wei  et al., 1999, 2002). DMAIII is thought to be the reac-
tive metabolite that produces changes in the urothelium associated
with exposure to DMAV. Development of urinary bladder tumors
in DMAV-exposed rats is possibly related to regenerative prolifera-
tion caused by the cytotoxic effect of the reactive metabolite DMAIII
(Cohen et al., 2006, 2007; Waalkes et al., 2006). In contrast, MMAV
is negative as a carcinogen in rat and mouse bioassays (Arnold
et al., 2006) but is a transplacental carcinogen in the mouse (Tokar
et al., 2012). Thus, because the metabolism of iAs forms methylated
metabolites that are more reactive and toxic than the parent com-
pound (Cohen et al., 2002; Petrick et al., 2000; Styblo et al., 2000), it
is likely that the methylated arsenicals contribute to the spectrum
of adverse health effects associated with chronic exposure to iAs
(Cohen et al., 2006).
Given the central role of arsenic methylation in the formation of
metabolites that mediate the toxic and carcinogenic effects asso-
ciated with chronic exposure to iAs, manipulation of the capacity
to methylate arsenic is one approach to understanding underlying
molecular processes. Studies in As3mt knockout mice have shown
that this enzyme plays a central role in the control of the dispo-
sition and retention of arsenic in arsenate-treated mice (Drobna
et al., 2009; Hughes et al., 2010). Studies of the effects of arsenite
exposure in wild-type and As3mt knockout mice have shown that
changes in the urothelium are qualitatively similar but more pro-
nounced in knockout mice than in wild-type mice (Chen et al., 2011;
Yokohira et al., 2010, 2011). The genotypic differences in the effects
of arsenite exposure on the urothelium can largely be explained by
the high retention of iAs in the urinary bladders of As3mt knockout
mice.
The present study examines effects on urothelial structure
after repeated exposure of wild-type and As3mt knockout mice to
DMAIII, the putative active metabolite of DMAV. Here, the As3mt
genotype affected morphological changes in the urothelium with a
greater response in As3mt knockout mice than in wild-type mice.
Evidence of regenerative proliferation in mice of either As3mt
genotype suggests that cytotoxicity and cell regeneration could
plausibly underlie urinary bladder tumorigenesis in the mouse.
2. Materials and methods
2.1. Chemicals
Dimethylarsinous iodide (DMAIII) was obtained from Eurolabs Ltd. (Cheshire,
UK) and stored desiccated at 2–8 ◦C. The purity of the chemical was  greater than
95%. Bromodeoxyuridine (BrdU) was purchased from (Sigma–Aldrich, St. Louis, MO).
Nembutal (Lundbeck, Deerfield, IL) was obtained from the Nebraska Medical Center
pharmacy.
2.2.  Animals
2.2.1. As3mt knockout mice
Four female and two male mice homozygous for the disrupted As3mt gene
(Drobna et al., 2009) were obtained from Dr. David Thomas (U.S. Environmental
Protection Agency, Research Triangle Park, NC). Exons 3 through 5 were deleted
by  homologous recombination to generate the As3mt KO homozygous mice. The
altered gene was introduced and maintained in strain 129S6 mice before being
introduced into strain C57BL/6 mice by marker-assisted accelerated backcrossing
performed by Charles River Laboratories (Wilmington, MA)  to produce homozy-
gous As3mt−/− mice. The mice were fertile, so brother/sister matings were used to
maintain the homozygous As3mt KO genotype. Twenty As3mt KO mice from the F6
generation, approximately 11 weeks old, were transferred from the breeding colony
at  the University of Nebraska Medical Center, Omaha, NE.
2.2.2. Wild type mice
Twenty female C57BL/6 mice (Charles River Breeding Laboratories, Kingston,
NY) approximately 11 weeks old at the time of arrival were used in the study.
2.3. Animal experiment
All animals were placed in an Association for Assessment and Accreditation of
Laboratory Animal Care International (AAALAC)-accredited facility and quarantined
for  7 days prior to treatment. The level of care provided met  or exceeded the basic
requirements outlined in the Guide for the Care and Use of Laboratory Animals
(National Research Council, 2011). The animals were housed in polycarbonate cages
(5  per cage) with micro-isolator tops and dry corncob bedding. Nestlets (Ancare,
Bellmore, NY) were placed inside the cages for environmental enrichment. Animals
were maintained at approximately 22 ◦C and 50% relative humidity with a 12-h
light/dark schedule, and were provided with pelleted Purina 5002 diet (Dyets Inc.,
Bethlehem, PA) and water (hyperchlorinated, RO) ad libitum throughout the study.
Animals were randomized into two groups per genotype. One  group in each
genotype served as the control and the other group was administered 77.3 ppm
dimethylarsinous iodide (equivalent to 25 ppm elemental arsenic that previously
produced urothelial hyperplastic changes in these mice after 4 weeks of treat-
ment (Yokohira et al., 2010, 2011)) in drinking water by injecting into water bags
(Hydropac® bags, Lab Products, Seaford, DE). Freshly prepared DMAIII was  injected
into bags just before replacement. The water bags in both the control and DMAIII-
treated groups were replaced once every two days.
The animals were treated for four weeks. One hour before sacrifice the mice were
injected with BrdU, 100 mg/kg intraperitonially. At sacrifice the urinary bladders
were inflated in situ with Bouin’s fixative, removed and placed in Bouin’s fixa-
tive  along with a small section of intestine. After fixation, bladders were weighed,
observed macroscopically and divided in half longitudinally. One  half of the bladder
was cut into longitudinal strips, embedded into paraffin with a slice of intestine,
sectioned and stained with hematoxylin and eosin for histopathological exami-
nation. A diagnosis of mild hyperplasia was made when there were four to five
cell layers in the bladder epithelium and moderate hyperplasia when six to eight
layers were present. Histopathological diagnosis is made without knowledge of
treatment group. The other half of each bladder was processed for examination
by  scanning electron microscopy (EM) and classified in one of five categories as
previously described (Cohen et al., 1990). The categories have the following char-
acteristics: class 1 bladders contain polygonal superficial urothelial cells; class 2
bladders have occasional small foci of superficial urothelial necrosis, especially in
the dome of the bladder; class 3 bladders have numerous small foci of superficial
urothelial necrosis; class 4 bladders have extensive superficial urothelial necro-
sis,  especially in the dome of the bladder; class 5 bladders have necrosis and
piling up (hyperplasia) of rounded urothelial cells. Normal animals show class 1
or  2, or occasionally class 3. Kidneys were removed, fixed in formalin, embed-
ded  in paraffin, sectioned and stained with hematoxylin and eosin and examined
histopathologically.
Unstained bladder and intestinal tissue slides were processed for immunohisto-
chemical detection of BrdU (Cohen et al., 2007). Intestinal tissue served as a positive
control. Anti-BrdU (Millipore Corporation, Temecula, CA) was used at a dilution of
1:200. The BrdU-labeled cells in at least 3000 urothelial cells were counted to deter-
mine a labeling index. Microscopic examination and counting of BrdU-labeled cells
was done on blinded slides.
2.4. Statistics
Comparison of all data collected on body weights, food and water consumption,
bladder weights, and the labeling index was  performed by the SAS general linear
models procedure and Duncan’s multiple range test. Selected intra-genotype and
inter-genotype comparisons for control and treated groups were performed. All
means are accompanied by calculation of standard errors. Histology results were
analyzed using Fisher’s Exact test (2-tail).
3. Results
3.1. General findings
All animals including treated KO mice showed no adverse signs,
and none died during the experimental period. There was  no signif-
icant difference in body weight or food and water intake between
respective groups. There was a statistically significant but small
increase of the relative kidney weight in treated compared to the
control knockout mice.
3.2. Histopathology
Simple hyperplasia was  observed in 4 of the 10 DMAIII-treated
knockout mice and only 2 of the 10 treated wild-type mice,
with none in the control knockout or wild-type mice (Fig. 1C,
F and Table 1). The superficial layer of the urothelium con-
tained eosinophilic intracytoplasmic granules (Suzuki et al., 2008)
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Figure 1. DMAIII-induced histopathological changes in the urothelium. Histopathological examination of the urothelium by hematoxylin and eosin staining showed normal
urothelium in knockout control mice (A) and the presence of eosinophilic intracytoplasmic granules in the superficial layer of the urothelium (B) and simple hyperplasia (C)
in  DMAIII-treated knockout mice. Similarly, wild-type control mice showed normal urothelium (D) and DMAIII-treated wild-type mice showed the presence of eosinophilic
intracytoplasmic granules (E) and simple hyperplasia (F). The granules in both knockout and wild-type mice appeared to be of various sizes and numbers per cell (B, E,
arrows). Magnification 1000× (A, B, D and E) and 200× (C and F).
in all DMAIII-treated mice (Fig. 1). Granules were round and of
varying sizes, with multiple granules occurring frequently in indi-
vidual cells (Fig. 1B, E). The granules were slightly smaller and fewer
in treated wild-type mice compared to treated knockout mice.
None of the control mice had granules (Fig. 1A, D). The granules
were present in the DMAIII-treated bladders whether they had sim-
ple hyperplasia or were normal. The kidneys showed no remarkable
changes by histopathological examination, except one mouse
in the knockout-treated group showed focal, chronic interstitial
inflammation.
Table 1
Effects of DMAIII treatment on the urinary bladder epithelium in mice. Mice were administered 77.3 ppm (equivalent of 25 ppm arsenic) through drinking water for 4 weeks.
The  urothelium was  investigated for hyperplasia by hematoxylin and eosin staining, BrdU labeling index by immunohistochemistry, and visualization by scanning electron
microscopy (EM).
Group Treatment Strain Histopathology BrdU labeling
index (%)
Mean ± S.E. (n)
SEM classification
Normal Simple hyperplasia 1 2 3 4
1 Control KO 10 0 0.11 ± 0.06 (9) 3 5 1 1
2  77.3 ppm DMAIII KO 6 4 0.75 ± 0.27 (9)a,b 2 4 4 0
3 Control WT 10 0 0.20 ± 0.14 (9) 3 5 2 0
4 77.3  ppm DMAIII WT 8 2 0.08 ± 0.03 (10) 5 4 1 0
a Significantly different compared to KO control group, p < 0.05.
b Significantly different compared to the WT DMAIII group, p < 0.05.
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Figure 2. Scanning electron microscopy (EM) examination of the bladder urothelium. Urothelium of control knockout mice was  normal in appearance (A, bar = 300 m)
whereas  necrosis and exfoliation of the superficial cells was present in the bladder urothelium from DMAIII-treated As3mt knockout mice (B, bar = 500 m).  In the wild-type
mice,  the urothelium was  normal in both control (C, bar = 200 m) and DMAIII-treated (D, bar = 300 m) groups.
3.3. Scanning electron microscopy
Although the changes visualized by EM were not statistically
significant, there was a clear trend for DMAIII-induced cytotoxicity
in the treated knockout mice compared to other groups (Table 1
and Fig. 2). The DMAIII-treated knockout mice had only 2 bladders
with class 1 changes and 4 bladders with class 2 changes, which are
considered normal for rodents (Cohen et al., 1990). However, four
bladders in the same group showed class 3 changes, which con-
tain numerous small foci of superficial urothelial necrosis (Fig. 2B),
whereas the knockout control group had 3 and 5 bladders with class
1 and class 2 changes (Fig. 2A), respectively, and only one each with
class 3 and class 4 changes. Among the wild type, DMAIII-treated
mice there was no significant cytotoxicity in the bladder by EM
compared to the control group (Fig. 2C, D).
3.4. BrdU labeling index
The DMAIII-treated knockout mice had a significantly increased
BrdU labeling index compared to the knockout control group and
also compared to the DMAIII-treated wild-type group of mice.
4. Discussion
Results of the present study showed that DMAIII administration
in drinking water for four weeks induced urothelial cytotoxicity
and regenerative urothelial cell proliferation in As3mt knockout
mice which was  somewhat greater compared to the treated wild-
type mice. DMAIII induced formation of intracytoplasmic granules
in the superficial urothelial cell layer in both wild-type and knock-
out mice. There were no instances of systemic toxicity in wild-type
or knockout mice.
DMAIII induced simple hyperplasia in more knockout mice
compared to wild-type mice, however the increase was  not statis-
tically significant. This was further demonstrated by a significant
increase in BrdU labeling index in treated knockout mice, indicat-
ing increased cell proliferation leading to simple hyperplasia; the
labeling index was  not increased in wild type mice. These results
are similar to what we  have observed for arsenite-administered
As3mt knockout compared to wild-type mice (Yokohira et al.,
2010, 2011). However, in the As3mt knockout mice, arsenite
induced more pronounced systemic toxicity at comparable doses
than in wild-type mice (Yokohira et al., 2010, 2011). This was
attributed to decreased clearance of arsenite in the As3mt knockout
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mice (Drobna et al., 2009; Yokohira et al., 2010, 2011). Methy-
lation enhances the clearance of arsenic through urine (Cohen
et al., 2006; Kenyon et al., 2008), but in As3mt knockout mice,
arsenic is cleared slowly and accumulates in the tissues (Chen
et al., 2011). In the current study, there was a significant dif-
ference between the DMAIII-induced effects in As3mt knockout
mice compared to wild-type mice, suggesting either that DMAIII
is not cleared as efficiently as in the wild-type mice, or loss
of As3mt function makes the urothelium more susceptible to
DMAIII. The first explanation is more likely. Mice are known to
methylate DMA  to TMAVO but only to a limited extent (Cohen
et al., 2006). DMA  (DMAIII + DMAV) remains the major metabo-
lite excreted in urine (Cohen et al., 2006). This suggests that
wild-type mice may  further methylate a significant quantity of
DMAIII to TMAVO, which is less reactive and less cytotoxic and
will reduce the net DMAIII excreted in the urine. Metabolic
and kinetic analyses are required to distinguish these possibili-
ties.
DMA  (DMAIII + DMAV) is the major metabolite in people exposed
to inorganic arsenic and also in rats and mice exposed to arse-
nate, arsenite, MMAV and DMAV (Cohen et al., 2006). Among the
arsenicals studied in 2-year bioassays DMAV was carcinogenic to
the bladder in rats but not mice (Arnold et al., 2006). Arsenate
and arsenite are carcinogenic to mice, although the carcinogenic
effect on the urothelium is limited (Cohen et al., 2007; Tokar
et al., 2010; Waalkes et al., 2006). Interestingly, MMAV was  not
carcinogenic to either mice or rats (Arnold et al., 2003). In short
term studies in rats, orally administered arsenate, arsenite and
DMAV induced urothelial hyperplasia, the preneoplastic prolifer-
ative lesion of the urothelium (Cohen et al., 2007). Arsenate and
arsenite also induced urothelial hyperplasia in mice, but DMAV did
not (Arnold et al., 2006; Cohen et al., 2006). The data in the cur-
rent study show that DMAIII also induces simple hyperplasia of
the urothelium in mice, suggesting a role for DMAIII in the inor-
ganic arsenic-induced pre-neoplastic changes and carcinogenic
effects.
We  have previously reported the detection of numerous intra-
cytoplasmic and intranuclear granules in AsIII-treated mice (Suzuki
et al., 2008; Yokohira et al., 2010, 2011). In this study, DMAIII
also induced intracytoplasmic granules in both As3mt knockout
and wild-type mice. These granules were confined to the super-
ficial layer and were seen in bladders with or without simple
hyperplasia. Our earlier study showed the presence of granules
in all layers of the urothelium in inorganic arsenic-administered
to As3mt knockout mice, and the severity of granule formation
was dose-dependent (Yokohira et al., 2010, 2011). Compared to the
arsenic-equivalent concentration of inorganic arsenic used in the
previous studies, the severity of granule formation by DMAIII was
less in terms of both number of granules and the layers of urothe-
lium affected. This may  be due to faster clearance of pre-methylated
DMAIII compared to non-methylated inorganic arsenic. The signif-
icance or the role of these granules in arsenic-induced toxicity is
still unclear.
The current study demonstrated that DMAIII induces urothe-
lial cytotoxicity and regenerative proliferation in As3mt knockout
mice and to a lesser extent in the wild-type mice, unlike DMAV
that did not induce any urothelial changes in wild type mice
(Arnold et al., 2006; Cohen et al., 2006). Similar to inorganic
arsenic, DMAIII induced formation of intracellular granules in
the urothelium of both As3mt knockout and wild-type mice,
though to a lesser extent than inorganic arsenic. These results
support our hypothesis that urothelial toxicity is induced by
reactive arsenicals, including DMAIII, which is a highly reactive,
trivalent methylated arsenical. Cytotoxicity is followed by regener-
ative proliferation resulting in hyperplasia and ultimately possibly
tumors.
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